Guarda, anche Etherum ha fatto una ICO quindi a rigor di logica non dovresti avere ETH nel tuo portafoglio. Facciamo una doverosa precisazione. Noi siamo una Biotech company che si occupa di ricerca scientifica. La ricerca scientifica è una cosa seria, le nostre pubblicazioni sono consultabili su pubmed (database governativo della NIH) e le nostre press release sono menzionate da più di 230 newsoutlets internazionali del calibro di Yahoo Finance e Bloomberg. Purtroppo c’è un ignoranza generale sulle ICO dovuta al fatto che molti non sanno fare neppure le ricerche piu elementari per distinguere progetti seri da scamcoins.

Copio dalla nostra FAQ.

ll ICOs are scam. What can you say about it?

​ICOs are a very valuable tool for our society, but you have to carefully check that the project is legit before investing. We can tell you this about our project. We are a biotech company performing novel biomedical research, and scientific research is something serious. One of the things that sets our ICO apart from the other ICO offerings is that it is based on our AIDS cure research. Behind our project there are therefore many years of hard work and investments to perform and publish our research. Investors with us know that they are investing into something real and concrete, and not in one of those bubble soap projects that disappear the day after the ICO because they are not solving any real issue and are just a collection of fancy presentations. With us, investors can easily verify that our project is something real and legit by checking the publications on the NIH database pubmed.

​
Fior J. An Initial In Vitro Investigation into the Potential Therapeutic Use of SupT1 Cells to Prevent AIDS in HIV-Seropositive Individuals. PLoS ONE. 2012;7(5):e37511. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22701517

Fior J. Is a pacific coexistence between virus and host the unexploited path that may lead to an HIV functional cure? Viruses. 2013;5(2):753-7. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23430684

Fior J. Salamander regeneration as a model for developing novel regenerative and anticancer therapies. J Cancer. 2014;5:715-9. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25258653

Fior J. SupT1 Cell Infusion as a Possible Cell-Based Therapy for HIV: Results from a Pilot Study in Hu-PBMC BRGS Mice. Vaccines. 2016;4(2):13. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27128948

Moreover, we are working on solving a real global issue such as developing a low cost cure solution for AIDS. There were 36.7million people infected by HIV globally in 2016, 17.5million of which were left untreated, according to UNAIDS. Our mission is to develop a low cost cell-based therapy solution for HIV to allow access to the treatment for those individuals who are normally left untreated due to social and/or economic limitations.